Poulenc Frères

Poulenc Frères was a French industrial and scientific-supply company whose roots lay in a Paris pharmacy established in 1827. The business initially operated as a pharmacy and druggist, but during the nineteenth century it developed a manufacturing and distribution role in chemicals used for photography, medicine, laboratory work, glassmaking, and ceramics. Étienne Poulenc and his associate Léon Wittman began preparing or packaging photographic chemicals in the 1850s, supplying materials for collodion photography and later for gelatin-silver photographic plates. Factories at Vaugirard and Ivry-sur-Seine produced or handled compounds such as silver bromide, silver iodide, iodine chloride, sodium thiosulfate, iron and antimony salts, ammonium ferric citrate, and sodium acetate. After Étienne Poulenc’s death in 1878, his widow and sons continued the enterprise. It was known as Veuve Poulenc et Fils from 1878 and adopted the name Poulenc Frères in 1881. The brothers Gaston, Émile, and Camille expanded the business beyond retail pharmacy and photographic chemistry. Poulenc Frères supplied laboratory apparatus, research reagents, pharmaceutical ingredients, inorganic iodides and bromides, photographic chemicals, and colorants for glass and ceramics. The company became particularly important as a supplier of relatively pure chemicals to pharmacists, researchers, and industrial users, although it distributed and packaged many products rather than manufacturing every item itself. Camille Poulenc brought a stronger research orientation to the family business. After training in pharmacy and science, he helped establish research facilities and a scientific library devoted to the preparation and control of mineral salts. His interest in chemistry and emerging medical technologies contributed to the company’s move into synthetic medicines. The firm’s relationship with researchers associated with the Pasteur Institute and French academic chemistry strengthened its pharmaceutical capabilities. Ernest Fourneau directed a pharmaceutical research department at Ivry-sur-Seine and, with Poulenc Frères, developed Stovaïne, or amylocaine, an early commercially successful synthetic local anesthetic patented at the beginning of the twentieth century. In 1900 the enterprise became the public limited company Établissements Poulenc Frères. At that time the Poulenc brothers retained approximately two-thirds of the capital. The company operated shops, laboratories, factories, and specialist facilities in Paris, Ivry, Montreuil, and later Vitry-sur-Seine. It expanded into photographic film, rayon, pharmaceutical chemistry, and organic products, while maintaining its established businesses in reagents and photographic supplies. A dedicated photography establishment opened in Paris in 1903, and a new Vitry plant built in 1907 became the main center for production transferred from Ivry. The First World War accelerated Poulenc Frères’ growth. French government contracts covered chemical-warfare materials and protective or therapeutic responses to poison gas. The company also manufactured substitutes for German medicines that had become difficult to obtain, including salvarsan and neo-salvarsan for syphilis treatment. Its workforce increased sharply during the war, and wartime demand helped finance further investment in synthetic-drug capacity. The company also maintained international technical links: an agreement with the British firm May & Baker allowed licensing of Poulenc patents, and Poulenc later acquired a controlling interest in May & Baker in 1927. Poulenc Frères survived the industrial disruption that followed the war and continued investing in pharmaceutical chemistry. In 1928 it merged with the Société chimique des usines du Rhône, a chemical company founded in 1895, creating Rhône-Poulenc. The merger ended Poulenc Frères as an independent company and combined its pharmaceutical and organic-chemical capabilities with Rhône’s industrial base. The resulting group became one of France’s leading organic-chemical producers outside the dye sector and ultimately formed part of the corporate lineage of modern French pharmaceutical and chemical businesses.

Poulenc Frères developed from the Pharmacie-Droguerie Hédouin, a Paris pharmacy founded in 1827 on the rue Saint-Merri. Pierre Wittman acquired the store in 1845, and his daughter Pauline later married the pharmacist and chemist Étienne Poulenc. Étienne entered into business with his father-in-law and became sole proprietor in 1858. Together with Léon Wittman, he began manufacturing and packaging photographic chemicals under the P.W. name. Production began at Vaugirard in the 1850s and moved into a larger chemical operation at Ivry-sur-Seine in 1859. The early manufacturing portfolio reflected the rapid development of nineteenth-century photography. It included silver bromide and iodide, iodine chloride, sodium thiosulfate, iron and antimony salts, and compounds used in gelatin-silver photographic plates. The firm also sold pharmaceutical, industrial, and laboratory chemicals. Its presence at the 1878 Universal Exposition demonstrated that the business had progressed beyond ordinary pharmacy retailing. After Étienne died in 1878, Pauline continued the enterprise with her sons. The company first became Veuve Poulenc et Fils and then Poulenc Frères in 1881. Gaston, Émile, and Camille expanded manufacturing and distribution in several directions. Poulenc Frères supplied laboratory apparatus and reagents, fine iodides and bromides for medical applications, pure elements and compounds for research, photographic chemicals, and colorants for glass and ceramics. It also introduced pharmaceutical substances including sodium methylarsenate, cacodylates, iron valerianate, quinine-related products, calcium albuminate, copper albuminate, naphthol, and phenol derivatives. Camille Poulenc was central to the company’s scientific transformation. Trained in pharmacy and science and influenced by Henri Moissan, he joined the family company after completing his studies. He helped create a research laboratory devoted to pure mineral salts and established a scientific library. His interest in radium and his contacts with Pierre and Marie Curie reflected the firm’s engagement with contemporary scientific research. More importantly, Camille promoted the use of organic and synthetic chemistry in medicines. In 1900 Poulenc Frères became Établissements Poulenc Frères, a public limited company backed by Banque privée Lyon-Marseille. The family retained about two-thirds of the capital. The company then operated multiple Paris premises, factories in Ivry, a colorant works at Montreuil, and additional facilities acquired or developed elsewhere. It exhibited at the 1900 Exposition Universelle, opened an animal-experiment laboratory, bought property at Vitry-sur-Seine, and acquired a small organic-products business at Livron-sur-Drôme. Its commercial scope widened to photographic film and rayon as well as pharmaceutical and laboratory chemistry. A specialist photographic establishment opened on the rue du Quatre-Septembre in Paris in 1903. That same year Ernest Fourneau took charge of a newly created pharmaceutical research department at Ivry. Fourneau’s work with the company led to Stovaïne, or amylocaine, an early synthetic local anesthetic whose patents were filed in 1903. Fourneau later directed therapeutic chemistry at the Pasteur Institute while maintaining links with Poulenc Frères. These institutional connections helped the company gain access to advanced French medical research. Poulenc built a new plant at Vitry-sur-Seine in 1907 and transferred production there from Ivry. Research and production expanded, and by 1913 the company employed hundreds of workers, including pharmacists, engineers, and chemists. It also pursued catalytic hydrogenation and recruited the chemist Jean-Baptiste Senderens to work at Vitry. Before the First World War, research teams including Fourneau and Francis Billon developed versions of synthetic medicines that had previously been associated with German manufacturers. The war brought exceptional demand. Government contracts covered chemical-warfare agents and gas antidotes, while import disruption created a market for French substitutes for German products. Poulenc Frères manufactured salvarsan and neo-salvarsan, among other medicines. Its workforce and sales grew substantially between 1914 and 1916. The company had already granted patent rights to May & Baker in 1909, with the licensing arrangement taking effect in 1916; the British company subsequently established a research laboratory for chemotherapeutic products. Poulenc Frères expanded synthetic-drug capacity after the war, survived the industrial crisis of 1920, and acquired control of May & Baker in 1927. The company ceased to exist independently in 1928 when it merged with the Société chimique des usines du Rhône. The new Rhône-Poulenc combined Poulenc’s pharmaceutical research and specialty-chemical activities with Rhône’s chemical manufacturing base. The merger created one of France’s leading organic-chemical enterprises outside dyes and established the corporate platform through which the Poulenc name continued in later pharmaceutical and chemical history.

• 1928

  Merger creates Rhône-Poulenc

  [1]Poulenc Frèresen.wikipedia.org

  Établissements Poulenc Frères merged with the Société chimique des usines du Rhône, ending Poulenc Frères as an independent company.

• 1927

  May & Baker control acquired

  [1]Poulenc Frèresen.wikipedia.org

  Poulenc Frères acquired a controlling interest in May & Baker after a long-standing patent and research relationship.

• 1914

  Wartime production begins

  [1]Poulenc Frèresen.wikipedia.org

  World War I increased demand for chemical-warfare materials, antidotes, and pharmaceutical substitutes.

• 1907

  Vitry-sur-Seine plant built

  [1]Poulenc Frèresen.wikipedia.org

  A new plant at Vitry-sur-Seine became the principal destination for production transferred from Ivry.

• 1903

  Stovaïne development and photography expansion

  [1]Poulenc Frèresen.wikipedia.org

  The company opened a specialist photography establishment in Paris and filed patents for Stovaïne with Ernest Fourneau.

• 1900

  Conversion into a public company

  [1]Poulenc Frèresen.wikipedia.org

  The business became Établissements Poulenc Frères and expanded its industrial, research, and commercial facilities.

• 1881

  Poulenc Frères name adopted

  [1]Poulenc Frèresen.wikipedia.org

  The company adopted the name Poulenc Frères as the Poulenc brothers became its leading family principals.

• 1878

  Business passes to the widow and sons

  [1]Poulenc Frèresen.wikipedia.org

  Following Étienne Poulenc’s death, Pauline Poulenc and her sons continued the enterprise under the name Veuve Poulenc et Fils.

• 1859

  Ivry chemical factory opens

  [1]Poulenc Frèresen.wikipedia.org

  A factory at Ivry-sur-Seine began preparing salts and photographic-processing compounds.

• 1852

  Entry into photographic chemicals

  [1]Poulenc Frèresen.wikipedia.org

  The business began preparing or packaging chemicals used in photographic processes.

• 1827

  Founding of the Paris pharmacy

  [1]Poulenc Frèresen.wikipedia.org

  The Pharmacie-Droguerie Hédouin was established on the rue Saint-Merri in Paris, providing the institutional origin of the later Poulenc business.

A science-led French supplier of high-purity chemicals, pharmaceutical materials, laboratory products, and photographic supplies, combining family ownership with increasingly formal industrial research.

• Synthetic pharmaceutical · 1903

  Stovaïne

  Stovaïne, also known as amylocaine, was an early commercially exploitable synthetic local anesthetic developed through the research work of Ernest Fourneau and Poulenc Frères. Patents were filed at the beginning of the twentieth century, and the medicine remained in use into the 1940s. Its development represented the company’s transition from supplying chemical ingredients to creating branded pharmaceutical products.

• Photography supplies · 1852

  Photographic chemicals

  Poulenc Frères supplied chemicals for several generations of photographic technology, beginning with collodion processes and continuing into gelatin-silver plates and later film. Its range included bromides, iodides, iodine chloride, sodium thiosulfate, iron compounds, developing agents, and fixing materials. The company was regarded as a leading French source of photographic chemical supplies.

• Scientific chemicals · 1881

  Laboratory reagents and mineral salts

  The company manufactured and distributed controlled-purity reagents and mineral salts for pharmacists, laboratories, researchers, and industrial users. Its portfolio included iron, antimony, tin, silver, lithium, chromium, molybdenum, iodides, bromides, and other inorganic compounds. Camille Poulenc’s research facilities sought to improve purity and consistency in this part of the business.

• Pharmaceuticals · 1914

  Salvarsan and neo-salvarsan

  During World War I, Poulenc Frères manufactured French-market supplies of salvarsan and neo-salvarsan, treatments for syphilis whose availability had been disrupted by the war. Their production formed part of the company’s broader effort to replace imported German synthetic medicines and support national wartime pharmaceutical capacity.

• Photography supplies · 1900

  Photographic film

  After building expertise in photographic chemistry, Poulenc Frères moved into the commercialization of photographic film. This extended the company beyond the supply of individual processing chemicals and connected its chemical manufacturing base with finished photographic materials.

• Industrial chemicals · 1890

  Glass and ceramic colorants

  Poulenc Frères produced colors and related chemical materials used in glass and ceramics. This activity diversified the company’s specialty-chemical business beyond pharmaceutical and photographic applications and made use of its expertise in metallic salts and inorganic compounds.

• 1928

  Merge with Société chimique des usines du RhôneM&A

  Background

  Poulenc Frères sought a larger industrial platform for its pharmaceutical and organic-chemical activities.

  Action taken

  Établissements Poulenc Frères merged with the Société chimique des usines du Rhône to create Rhône-Poulenc.

  Aftermath

  Poulenc Frères ceased to operate as an independent company, while its research, pharmaceutical, and specialty-chemical capabilities became part of Rhône-Poulenc.

  Source

• 1927

  Acquire control of May & BakerM&A

  Background

  Poulenc Frères and May & Baker had maintained a patent-licensing and research relationship since the prewar period.

  Action taken

  Poulenc Frères acquired a controlling interest in the British company.

  Aftermath

  The acquisition extended Poulenc’s international pharmaceutical and research position immediately before its merger with Rhône.

  Source

• 1914

  Shift capacity toward wartime chemicals and medicinesStrategy

  Background

  World War I disrupted imports and generated government demand for chemical-warfare materials, antidotes, and substitute medicines.

  Action taken

  The company accepted government production contracts and manufactured products including salvarsan and neo-salvarsan.

  Aftermath

  Wartime demand substantially increased the company’s workforce and sales and encouraged postwar investment in synthetic-drug production.

  Workforce. Approximately 500 employees in 1914 → Approximately 2,000 employees in 1916 (1914-1916)

  Source

• 1907

  Consolidate production at Vitry-sur-SeineStrategy

  Background

  Growing pharmaceutical and chemical operations required additional industrial capacity.

  Action taken

  Poulenc Frères built a new plant at Vitry-sur-Seine and transferred factories there from Ivry.

  Aftermath

  Vitry became a major center for the company’s expanding research and manufacturing activities.

  Source

• 1903

  Commercialize StovaïneProduct launch

  Background

  Camille Poulenc’s research orientation and Ernest Fourneau’s appointment created a dedicated platform for synthetic pharmaceutical development.

  Action taken

  Poulenc Frères and Fourneau patented Stovaïne, an early synthetic local anesthetic.

  Aftermath

  The product became an important early success in the company’s move into synthetic medicines and remained in use until the 1940s.

  Source

• 1900

  Convert the family business into a public companyStrategy

  Background

  The expanding pharmacy, chemical-supply, and manufacturing business required a broader corporate structure and additional capital.

  Action taken

  Poulenc Frères was reorganized as Établissements Poulenc Frères, while the three brothers retained approximately two-thirds of the capital.

  Aftermath

  The new structure supported further factory construction, research investment, and expansion into pharmaceuticals, film, and rayon.

  Source

1. 1Poulenc Frèresen.wikipedia.org